UPDATE 3-Double blow for Roche as breast cancer, Alzheimer's studies fail

UPDATE 3-Double blow for Roche as breast cancer, Alzheimer's studies fail

… * Breast cancer study fails to prove added Kadcyla benefit. * Ending Phase III trial with Alzheimer's drug gantenerumab. * Roche shares fall 5.4 percent, most in five years. * MorphoSys down 9.3 pct, ImmunoGen off 27 pct in premarket (Adds latest

7
Like
Save

Comments

Write a comment

*